CTOR Quote, Financials, Valuation and Earnings

Merck & has a net margin of -- compared to Citius Oncology's net margin of 18.95%. Citius Oncology's return on equity of -- beat Merck &'s return on equity of 29.26%.

Citius Oncology has a consensus price target of $3.00, signalling upside risk potential of 183.02%. On the other hand Merck & has an analysts' consensus of $127.05 which suggests that it could grow by 27.49%. Given that Citius Oncology has higher upside potential than Merck &, analysts believe Citius Oncology is more attractive than Merck &.

Citius Oncology has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Merck & has a beta of 0.390, suggesting its less volatile than the S&P 500 by 60.989%.

Citius Oncology has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Merck & offers a yield of 3.13% to investors and pays a quarterly dividend of $0.81 per share. Citius Oncology pays -- of its earnings as a dividend. Merck & pays out 2039.73% of its earnings as a dividend.

Citius Oncology quarterly revenues are --, which are smaller than Merck & quarterly revenues of $16.7B. Citius Oncology's net income of -- is lower than Merck &'s net income of $3.2B. Notably, Citius Oncology's price-to-earnings ratio is -- while Merck &'s PE ratio is 20.89x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Citius Oncology is -- versus 4.01x for Merck &. Usually stocks with elevated PS ratios are considered overvalued.

NovaBay Pharmaceuticals has a net margin of -- compared to Citius Oncology's net margin of -49.65%. Citius Oncology's return on equity of -- beat NovaBay Pharmaceuticals's return on equity of -461.38%.

Citius Oncology has a consensus price target of $3.00, signalling upside risk potential of 183.02%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $7.30 which suggests that it could grow by 423.91%. Given that NovaBay Pharmaceuticals has higher upside potential than Citius Oncology, analysts believe NovaBay Pharmaceuticals is more attractive than Citius Oncology.

Citius Oncology has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.646, suggesting its less volatile than the S&P 500 by 35.372%.

Citius Oncology has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Citius Oncology pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

Citius Oncology quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Citius Oncology's net income of -- is lower than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, Citius Oncology's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Citius Oncology is -- versus 0.08x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Predictive Oncology has a net margin of -- compared to Citius Oncology's net margin of -895.23%. Citius Oncology's return on equity of -- beat Predictive Oncology's return on equity of -232.54%.

Citius Oncology has a consensus price target of $3.00, signalling upside risk potential of 183.02%. On the other hand Predictive Oncology has an analysts' consensus of -- which suggests that it could grow by 150%. Given that Citius Oncology has higher upside potential than Predictive Oncology, analysts believe Citius Oncology is more attractive than Predictive Oncology.

Citius Oncology has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Predictive Oncology has a beta of 1.182, suggesting its more volatile than the S&P 500 by 18.224%.

Citius Oncology has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Predictive Oncology offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Citius Oncology pays -- of its earnings as a dividend. Predictive Oncology pays out -- of its earnings as a dividend.

Citius Oncology quarterly revenues are --, which are smaller than Predictive Oncology quarterly revenues of $345.7K. Citius Oncology's net income of -- is lower than Predictive Oncology's net income of -$3.1M. Notably, Citius Oncology's price-to-earnings ratio is -- while Predictive Oncology's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Citius Oncology is -- versus 3.80x for Predictive Oncology. Usually stocks with elevated PS ratios are considered overvalued.

Revance Therapeutics has a net margin of -- compared to Citius Oncology's net margin of -63.65%. Citius Oncology's return on equity of -- beat Revance Therapeutics's return on equity of --.

Citius Oncology has a consensus price target of $3.00, signalling upside risk potential of 183.02%. On the other hand Revance Therapeutics has an analysts' consensus of $7.64 which suggests that it could grow by 132.13%. Given that Citius Oncology has higher upside potential than Revance Therapeutics, analysts believe Citius Oncology is more attractive than Revance Therapeutics.

Citius Oncology has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Revance Therapeutics has a beta of 0.857, suggesting its less volatile than the S&P 500 by 14.274%.

Citius Oncology has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Revance Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Citius Oncology pays -- of its earnings as a dividend. Revance Therapeutics pays out -- of its earnings as a dividend.

Citius Oncology quarterly revenues are --, which are smaller than Revance Therapeutics quarterly revenues of $59.9M. Citius Oncology's net income of -- is lower than Revance Therapeutics's net income of -$38.1M. Notably, Citius Oncology's price-to-earnings ratio is -- while Revance Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Citius Oncology is -- versus 1.24x for Revance Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.